Pfizer shares were lower on Tuesday despite third-quarter financial results that came in ahead of expectations. Sales of a ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Concerns about the company's future growth are likely keeping investors away.

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

Pfizer offers an annual dividend yield of 6.98%, or $1.72 a year. Here's how investors can pocket a regular $500 monthly.

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing ...

The Metsera deal is about winning the obesity drugs' market that’s expected to reach US$100 billion by 2030. Read more at ...

Investing.com - U.S. stock futures rose sharply Monday after the Senate voted in favor of a bill aimed at ending the ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking in Washington. A new bill quickly advanced in a key S ...